Patrick Round

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

G. Kees Hovingh, John J.P. Kastelein, Sander J. H. van Deventer et al. · The Lancet · 2015 · 228 citations · Full text

Metabolic Syndrome, Placebo-controlled Phase 2, Lipid Disorder +9

XEN-D0501, a Novel Transient Receptor Potential Vanilloid 1 Antagonist, Does Not Reduce Cough in Patients with Refractory Cough

Maria G. Belvisi, Mark A. Birrell, Michael A. Wortley et al. · American Journal of Respiratory and Critical Care Medicine · 2017 · 153 citations · Full text

The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation

John W. Ford, J. Milnes, Saïd El Haou et al. · Heart Rhythm · 2015 · 68 citations · Full text

An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN‐D0501 in healthy subjects

Patrick Round, Anthony Priestley, Jan Robinson · British Journal of Clinical Pharmacology · 2011 · 62 citations · Full text

Tolerability, pharmacokinetics and pharmacodynamics of <scp>TA</scp>‐8995, a selective cholesteryl ester transfer protein (<scp>CETP</scp>) inhibitor, in healthy subjects

J. Ford, Matt Lawson, D. E. Fowler et al. · British Journal of Clinical Pharmacology · 2014 · 49 citations · Full text